Day One Biopharmaceuticals Total Revenue

The latest total revenue for DAWN is $160M as of December 2025. That compares with $57M in the prior-year period — up 175.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Day One Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, DAWN's total revenue moved from $57M to $160M — a 175.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Day One Biopharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, DAWN currently prints $160M for total revenue, while the sector average sits near $110B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Day One Biopharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $160M for DAWN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting DAWN's total revenue ($160M), review year-over-year change from $57M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.